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an American College of Cardiology (ACC) and American Heart
Association (AHA) clinical practice guideline (CPG). This joint
effort was undertaken in response to the U.S. government’s
request to review the evidence concerning cardiac pacemakers
and develop CPGs to mitigate potential overuse. Since then,
fueled by a shared sense of responsibility to translate available
evidence into clinical practice to guide cardiovascular clini-
cians, the ACC and AHA have developed 23 CPGs across the
spectrum of cardiovascular diseases and procedures.The “why” and “how” of CPGs continue to evolve. Although
the “why” is based on the directive to develop evidence-based
recommendations for selection of diagnostic tests, proce-
dures, and treatments to improve quality of care and out-
comes for patients with cardiovascular disease, it is precisely
where evidence is lacking or is controversial that clinicians
need the most guidance. A 2012 survey of ACC and AHA
members provides important insight into the way clinicians
and other healthcare professionals apply CPGs; further details
are provided below. The results highlight a natural tensionrd of Trustees and the American Heart Association Science Advisory and
s follows: Jacobs AK, Anderson JL, Halperin JL. The evolution and future of
erican College of Cardiology/American Heart Association Task Force on
merican College of Cardiology (www.cardiosource.org) and the American
se contact the Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail
/or distribution of this document are not permitted without the express
d online via the Elsevier site (http://www.elsevier.com/ authors/obtaining-
Jacobs et al. J A C C V O L . 6 4 , N O . 1 3 , 2 0 1 4
Evolution and Future of ACC/AHA CPGs S E P T E M B E R 3 0 , 2 0 1 4 : 1 3 7 3 – 8 4
1374between the needs of clinicians for comprehensive clin-
ical advice from seasoned experts and for a clear delin-
eation of diagnostic and therapeutic measures for which
strong scientiﬁc evidence exists.
Notably, there has been an increased focus on the
“how” of CPGs and changes in the methodology used to
collect and evaluate the evidence. In 2011, the Institute
of Medicine (IOM) published 2 reports, Clinical Practice
Guidelines We Can Trust (1) and Finding What Works in
Health Care: Standards for Systematic Reviews (2). In
response to these reports and our own mandate to con-
tinually improve processes and methods while evaluat-
ing the continuous stream of new knowledge and
maintaining relevance at the point of care, the ACC/AHA
Task Force on Practice Guidelines (Task Force) held a
Methodology Summit in December 2011. The Method-
ology Summit focused on the standards for systematic
reviews and process improvements. The response to the
21 standards and 82 supporting elements proposed by the
IOM was published in the “ACCF/AHA Clinical Practice
Guideline Methodology Summit Report” (3). However,
many of the IOM recommendations and standards are
themselves based more on consensus than data, and
there is little evidence on the extent to which their
implementation may have a favorable impact on clinical
outcomes. Hence, the effectiveness of the IOM report
recommendations must be assessed over time as organ-
izations similar to the ACC and AHA begin the complex
process of applying the proposed standards in CPG
development.
During the past few years, several process improve-
ment initiatives have been implemented to limit the
narrative text in CPGs by substituting increased use of
summary and evidence tables (with references linked to
abstracts in PubMed). Consensus conferences at which
members of guideline writing committees (GWCs) reach
agreement and concordance on overlapping recom-
mendations are now held routinely. Methodological
enhancements include development and future vali-
dation of a scoring tool to consistently assess the quality
of randomized trials that inform recommendations in the
domains of bias, relevance, and ﬁdelity. In addition, an
analysis of Bayesian approaches to evidence synthesis
was undertaken (4). Other enhancements include sepa-
ration of the Class III recommendations to delineate
whether the recommendation is determined to be of “no
beneﬁt” or associated with “harm” to the patient, as
well as inclusion of comparative-effectiveness recom-
mendations based on comparative-effectiveness studies
to indicate when one treatment/strategy is preferred to
another. Lastly, to harmonize with other CPG classi-
ﬁcation schema, we now more precisely indicate the
strength of the recommendation associated with the Class
of Recommendation (COR).RATIONALE FOR CPGS
In the IOM report (1), CPGs were redeﬁned as follows:
Clinical practice guidelines are statements that
include recommendations intended to optimize
patient care that are informed by a systematic review
of the evidence and an assessment of the beneﬁts and
harms of alternative care options.
CPGs that are rigorously developed have the potential
to improve the quality of cardiovascular care, lead to
better patient outcomes, improve cost-effectiveness by
targeting resources to the most effective therapies,
enhance the appropriateness of clinical practice, and
identify critical gaps in evidence and areas needing
additional research. In fact, when patients are treated
according to ACC/AHAClass I recommendations, outcomes
are improved. Speciﬁcally, data from the quality of care
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines) Registry demon-
strate that in patients with acute coronary syndromes,
there is a 10% reduction in in-hospital mortality for every
10% increase in adherence to ACC/AHA Class I guideline-
directed medical therapies (5). Similarly, data from
ADHERE (Acute Decompensated Heart Failure National
Registry) demonstrate that patients treated according to
heart failure performance indicators have a signiﬁcant
reduction in in-hospital mortality and length of stay (6).
DEVELOPMENT PROCESS
The Task Force, which is composed of a broad con-
stituency with varying content expertise, oversees and
directs the CPG development process and methodology
that are the foundation of the documents and the
underpinning of their broad recognition. The process
begins with selection of a topic for a new, revised, or
updated CPG by the Task Force with the input of GWCs
and ACC and AHA council and committee members. In
view of the overarching goal of inclusivity and collabo-
ration, selected organizations and professional societies
with similar interests and expertise are invited to partic-
ipate as partners or collaborators. Next, a GWC chair is
selected by the Task Force, and, with input from the
leadership of participating organizations, potential
members of the GWC are identiﬁed, based on a detailed
and speciﬁc policy on relationships with industry and
other entities (RWI) and a desire to balance intellectual
and practice perspectives in addition to sex, race, geo-
graphic location, and ethnicity. In view of the AHA’s focus
on the patient and the public it serves and its lay mem-
bership, the ACC’s initiative on patient-centered care, and
the recommendations of the Methodology Summit, the
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patient advocates, or consumer organization representa-
tives) to participate as members of GWCs and may include
them on the Task Force. Methods to identify, select, train,
and manage RWI and the intellectual perspectives of lay
representatives are in development. Lay representatives
may participate in topic selection; delineation of diag-
nostic and therapeutic options, values, preferences, and
patient-oriented outcomes; and shared decision making.
The GWC outlines the document content, performs
a detailed and speciﬁc evidence acquisition and review,
and drafts recommendations based on the strength and
quality of evidence with limited preliminary text. On the
basis of the Methodology Summit recommendations, the
process has started to involve an Evidence Review Com-
mittee (ERC) that is separate from the GWC. The ERC
includes methodologists, epidemiologists, clinicians, and
biostatisticians tasked with formal systematic review of
available evidence and responsibility for identiﬁcation,
abstraction, and quality assessment of the evidence.
Given practical considerations, including limited resour-
ces and time constraints, the role of ERCs will be limited
to addressing critical questions where the evidence lends
itself to a systematic review and that are most clinically
relevant to the CPG topic. The role of the ERC in selected
CPGs may be fulﬁlled by a partnership with other highly
regarded organizations that perform systematic reviews,
such as the National Institutes of Health, the Cochrane
Collaborative, and Kaiser Permanente. When appropriate,
other stakeholders may be invited. In 2013, the Task ForcePC
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UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.successfully piloted a focused ERC approach to a conﬁned
topic using a PICOTS (Population, Intervention, Com-
parator, Outcomes, Timing, and Setting) format to
develop critical questions for the systematic review. The
PICOTS format speciﬁcally identiﬁes the target pop-
ulation (P) for whom the intervention is intended; deﬁnes
the intervention (I) and whether the comparator (C) is
placebo, no intervention, or some alternative strategy;
designates the outcome (O) as a clinical event (e.g.,
mortality, nonfatal myocardial infarction) or a patient-
oriented endpoint (e.g., symptoms, functional capacity,
quality of life, diagnosis, or prognosis); and speciﬁes
the timing (T) of measurement for the intended outcome
and the setting (S) in which the outcome is measured.
Developing appropriate questions is a collaborative
process, with input from the GWC chair and members,
the Task Force, partner organizations involved with the
CPG, and the ERC. The questions may also be reviewed
more broadly by organizational leadership and the
public. It is then the responsibility of the GWC to develop
recommendations using the evidence reviewed by the
ERC.
Once recommendations and limited text are drafted,
the vetting process begins. In the absence of new evi-
dence, prior recommendations in ACC/AHA CPGs do not
change. Because recommendations often overlap across
multiple documents (Figure 1), reconciliation can be
complex and time consuming. The ﬁrst consensus con-
ference was held in 2009 and attended by members of
the GWCs of the percutaneous coronary intervention,I
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1376coronary artery bypass surgery, and ST-elevation myo-
cardial infarction CPGs all of which were under revision.
With input from the stable ischemic heart disease GWC,
the attendees crafted a combined section on coronary
revascularization for inclusion in all 3 CPGs. The con-
sensus conference approach broadens input on related
recommendations, facilitates consensus, enhances
implementation at the point of care, expedites the CPG
development process, and promises to be useful in similar
future applications.
Although usually approved by consensus, every rec-
ommendation is ratiﬁed by a majority of votes by the
members of the GWC; those members with relevant RWI
are required to recuse themselves from voting on sections
to which their speciﬁc RWI applies. The ﬁnished docu-
ment then undergoes peer review by ACC and AHA ofﬁcial
reviewers, content experts (many of whom serve on ACC
and AHA councils and committees), participating organ-
izations, and the Task Force (Figure 2). The peer review
process has been expanded to encompass a broad spec-
trum of relevant stakeholders, including lay representa-
tives and constituencies and governmental agenciesOfficial ACC
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GWC
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Official AHA
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FIGURE 2 ACC/AHA CPG Peer Review Process
ACC indicates American College of Cardiology; AHA, American Heart Associationwhen appropriate (e.g., the Agency for Healthcare
Research and Quality and the U.S. Food and Drug
Administration).
Each peer reviewer’s comment is reviewed by the chair
and members of the GWC, and a response is generated; it
is not unusual to receive >1,000 comments from peer
reviewers. A lead reviewer from the Task Force ensures
appropriate reconciliation of all peer reviewer comments.
Changes in recommendations require approval by a for-
mal vote of the members of the GWC according to the
voting policy. The document then requires ratiﬁcation by
the ACC Board of Trustees, the AHA Science Advisory and
Coordinating Committee, and partnering or collaborating
organizations. After thorough vetting within the aca-
demic and clinical communities and the leadership of the
ACC and AHA, the CPG is jointly published in the Journal
of the American College of Cardiology, Circulation, and the
ﬂagship journals of partnering and collaborating organ-
izations as appropriate. Once published, CPG recom-
mendations become the ofﬁcial policy of both the ACC
and AHA, informing strategic initiatives, advocacy, edu-
cation programs, and services. To accelerate access tosensus
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1377CPGs that have received ﬁnal approval, the ACC and AHA
release the manuscripts before typesetting, allowing the
documents to be available nearly 2 months ahead of for-
mal publication in the journals.
RELATIONSHIPS WITH INDUSTRY
AND OTHER ENTITIES
The validity and reliability of CPGs have been questioned,
based on concerns that the CPGs are composed by indi-
viduals with perceived conﬂicts of interest (COI), primarily
due to RWI engaged in the development or marketing of
medical technology or pharmaceutical agents. The per-
ception that all RWI imply COI is not inherently accurate
(7,8). There is no evidence to conﬁrm or deny that RWI
lead to a bias in writing recommendations, and the quan-
titative impact of RWI is unknown. Bias may also exist
without RWI, and individuals with RWI often have the
greatest expertise in the subject.
Even so, strict policies are in place to prevent undue
inﬂuence of commercial or other special interests on the
CPG development process (9). In late 2009, well in
advance of the IOM report, policies were updated to
require more rigorous management of RWI. The ACC and
AHA believe that, when transparent and properly man-
aged, including experts with RWI on GWCs strengthens
the writing effort and results in improved documents by
ensuring the availability of necessary expertise. The 2011
Methodology Summit participants supported this view,
noting that the “absence of experts (perhaps with rele-
vant RWI) on the GWC would undermine the credibility of
the review and CPG as much or more than the presence of
committee members with RWI” (3). Moreover, the term
“RWI” is preferred over “COI” because the former does
not imply ethically conﬂicting interests or objectives.
In addition to managing RWI, the ACC and AHA mon-
itor and manage other potential biases that may be rele-
vant to the writing effort, including academic settings,
race, sex, geography, intellectual stance, or scope of
clinical practice. On the basis of the Methodology Summit
recommendations, the intellectual (referring to prior
published opinion or research) and practice (applying
when an individual’s income is enhanced by or derived
from reimbursement for performing speciﬁc tests or pro-
cedures) perspectives relevant to the guideline topic are
recognized, deﬁned, disclosed, and managed. As with the
choice of the term “RWI” rather than “COI,” the ACC and
AHA have chosen the terms “intellectual perspective” and
“clinical practice perspective” (rather than bias) to denote
intellectual and practice-related opinions and expertise
based on knowledge or experience.
To address these issues, the ACC and AHA rely on the
principles of deﬁne, disclose, and manage. The relevance,
scope, and level of RWI are clearly deﬁned. For thepurpose of identifying a chair and/or member of a GWC,
the following criteria are used to determine if a relevant
relationship with a company or other entity exists:
 The relationship or interest relates to the same or sim-
ilar subject matter, intellectual property or asset, topic,
or issue addressed in the document; or
 The company/entity (with whom the relationship
exists) makes a drug, drug class, or device addressed in
the document or makes a competing drug or device
addressed in the document; or
 The person or a member of the person’s family or
household has a reasonable potential for ﬁnancial,
professional, or other personal gain or loss as a result of
the issues/content addressed in the document.
In terms of scope, the ACC and AHA require disclosure
of all RWI (comprehensive for the previous 12 months)
involved in the production, marketing, distribution, or
reselling of healthcare goods, services, advice, or infor-
mation consumed by patients, investors, or physicians.
This may include relationships with government entities
as well as not-for-proﬁt institutions and organizations,
which differs from and is more comprehensive than the
IOM standards. In addition, authors are strongly dis-
couraged from engaging in new RWI until the document
has been approved by the organizations and published.
The amount or level of RWI is deﬁned as:
 None—If the individual has no conﬂicts or relationships
to disclose, he or she must indicate none.
 Modest (<$10,000)—A relationship is considered mod-
est if it is less than signiﬁcant. (In the fall of 2014, this
will change to <$5,000 to align with U.S. Public Health
Service regulations.)
 Signiﬁcant ($$10,000)—A person is deemed to have a
signiﬁcant interest in a business if it represents own-
ership of $5% of the voting stock or share of the
entity, ownership of $$10,000 of the fair market value
of the entity, or if funds received from the entity
exceeded 5% of the individual’s gross income during
the prior year. (In the fall of 2014, this will change
to $$5,000 to align with U.S. Public Health Service
regulations.)
Disclosure of relationships of members of the GWC is
performed as follows:
 In advance—RWI are reviewed and vetted during ini-
tiation of the GWC to ensure fair balance on the GWC.
 On an ongoing basis—verbally and in writing at the start
of every meeting and conference call.
 Published—in print and online using a tabular format to
highlight type and level of relationship; publication
of all relevant relationships for authors and peer re-
viewers with each guideline, including documentation
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1378of sections from which authors recused themselves
from writing or voting; and online posting of compre-
hensive RWI for each author and oversight Task Force
member.
Reporting categories include consultancies, speakers
bureaus, ownership, partnerships, principal roles, research
support, salary, institutional and organizational relation-
ships, and expert witness activities.
Management of RWI involves selection of a balanced
GWC and requires that both the chair and a majority of
members have no relevant RWI. Authors are restricted
with respect to writing or voting on sections to which
RWI apply. Although they are permitted to participate in
discussion and comment on the draft, the chair is
responsible for ensuring that this does not result in
undue or unfair inﬂuence. All CPG recommendations
require approval by a majority of the members of the
GWC without relevant RWI through conﬁdential ballot-
ing. Members recused from voting are listed in the RWI
table. Members of the ﬁnal approving bodies of the
ACC Board of Trustees and AHA Science Advisory and
Coordinating Committee also recuse themselves from
voting if they have relevant RWI. The RWI of GWC
members and peer reviewers pertinent to the CPG are
located in the Appendix. In addition, to ensure complete
transparency, comprehensive disclosure information—
including RWI not pertinent to the document—is avail-
able online for all members of the GWC, as is disclosure
information for the entire Task Force. The creation of
CPGs and the work of the GWC are supported exclusively
by the ACC, AHA, and partnering organizations without
commercial support. Members of the GWC and Task
Force volunteer for this activity without compensation.
The ACC and AHA are fully committed to transparency in
the development of CPGs, have aligned RWI policies
with respect to CPG documents, and continuously eval-
uate these policies.
RECOMMENDATION CLASSIFICATION SYSTEM
In analyzing evidence and developing recommendations,
GWCs use benchmarks developed by the Task Force (9).
The COR is a statement of the strength of the recom-
mendation and continues to serve as the primary guide
for clinicians. The choice of the COR may involve con-
sideration of an estimate of the size and strength of the
effect of the intervention (diagnostic test or therapeutic
strategy, medication, device, procedure, or other inter-
vention) and the magnitude of beneﬁt in relation to risk.
The Level of Evidence (LOE) describes the certainty or
precision of the information supporting the recom-
mendation based on the type and quality of the evidence.
Class I and III recommendations are considered strong
recommendations and are based on size, strength, andpositive or negative beneﬁt–risk estimate of the effect and
generalizability of beneﬁt over risk. Class IIa recom-
mendations carry intermediate strength and correspond
to less beneﬁt in proportion to risk. Class IIb recom-
mendations, the weakest, address measures associated
with marginal beneﬁt–risk ratios or uncertain outcome
advantages and suggest that additional evidence is nee-
ded to clarify the relative beneﬁt–risk of the intervention.
Class III recommendations are unique in that they have
2 qualiﬁers. Class III: Harm is a strong recommendation
usually derived from 1 or more trials in which outcomes
were worse with the intervention than with the control.
Class III: No Beneﬁt is a moderate recommendation that is
applied infrequently when evidence suggests that a
strategy is no better than the control. Class III: No Beneﬁt
recommendations should not be associated with weak
evidence or expert opinion—LOE C or E—because it is
virtually impossible to ascertain lack of beneﬁt without
randomized trials or carefully conducted observational
studies when safety is not the primary concern. Class III:
No Beneﬁt recommendations should be supported by
moderate or high-quality evidence. The adequacy of the
supporting data, including sample size and event rates,
needs careful consideration based upon objective criteria
(i.e., validated grading tools).
The LOE rates the precision and quality of the scientiﬁc
evidence supporting the effect of an intervention based
on the type, quantity, consistency, and quality of clinical
trials and other relevant evidence. The ERC or GWC
grades the evidence supporting each recommendation,
depending on whether this includes randomized, obser-
vational, prospective, or retrospective studies, and their
quality, including objectively deﬁned criteria for assess-
ment of potential bias in addition to their relevance
and ﬁdelity. When published scientiﬁc evidence is lack-
ing, a consensus of expert opinion is sought to gauge
standards of care based on clinical experience and ranked
as Level E.
To accommodate the more quantitative, graded
approach to evidence assessment, the Task Force has
cautiously modiﬁed the COR/LOE schema (Table 1) to
provide additional categories that offer greater gran-
ularity with separate categories for randomized and
nonrandomized/observational evidence to deﬁne the
level and quality of evidence. The COR/LOE schema
continues to evolve as we reﬁne tools to assess the quality
of evidence and collaborate with other organizations such
as the European Society of Cardiology to enhance the
clarity, accuracy and utility of guideline recom-
mendations. Suggested phrases for writing recom-
mendations are provided in the interest of consistency.
The revised grading schema consists of the following
categories, with studies assessed by the GWC or (selec-
tively) the ERC, increasingly using standardized evidence
TABLE 1
Applying Class of Recommendations and Level of Evidence to Clinical Strategies, Interventions, Treatments, or
Diagnostic Testing in Patient Care*
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ation of the quality of evidence:
 Level A
B High-quality evidence* from more than 1 randomized
controlled trial (RCT)
B Meta-analyses of high-quality RCTs
B One or more RCTs corroborated by high-quality reg-
istry studies
 Level B-R (Randomized)
B Moderate-quality evidence* from 1 or more RCTs
B Meta-analyses of moderate-quality RCTs
 Level B-NR (Nonrandomized)
B Moderate-quality evidence* from 1 or more well-
designed, well-executed nonrandomized studies,
observational studies, or registry studies
B Meta-analyses of such studies
 Level C
B Randomized or nonrandomized observational or reg-
istry studies with limitations of design or execution
B Meta-analyses of such studies
B Physiological ormechanistic studies in human subjects
 Level E
B Consensus of expert opinion based on clinical experi-
ence when evidence is insufﬁcient, vague, or
conﬂicting
In view of the increasing number of studies involving active
controls rather than placebos, recommendations addressing
the relative effectiveness of one clinical strategy compared
with another continue to be included with speciﬁc phrase-
ology. These apply to COR I and IIa recommendations only
and to LOE A or B-R/B-NR.
To address the concern about coupling the strong COR
categories I and III with lower LOEs or expert opinion,
speciﬁc new guidance from the Task Force is being given
to GWCs as follows: Class I recommendations based only
on LOE C/E should be minimized, and Class III: No Beneﬁt
recommendations should be avoided whenever possible if
supported only by LOE C/E.
An analysis of the 3,271 recommendations across 19
CPGs published by 2013 showed that nearly 50%were Class
I recommendations. In addition, 50% of recommendations
were informed by LOE C and <10% were based on LOE A.
Of the Class I recommendations, only 11% were based on
LOE A, and 46% were informed by LOE C; even fewer were
assigned LOE A within COR IIa, IIb, and III. Taken together,
these results indicate an important gap in evidence sug-
gesting a need for clinical trial evidence in the future.
Across CPGs, the proportion of LOE C recommendations* The method of assessing quality is evolving, including the application of
standardized, widely used, and preferably validated evidence grading tools;
and for systematic reviews, the incorporation of an ERC.has prompted criticism and questions about whether CPGs
should deﬁne the standard of care (8,10). Yet, when evi-
dence is weak, conﬂicting, or absent, clinicians seek and
need the most guidance. Moreover, it is recognized that
certain LOE C recommendations that represent common
sense and conventional wisdom are unlikely to be studied.
However, a review of past LOE C recommendations sug-
gested that many were, in fact, supported by lower levels
of evidence as well as expert opinion. Overall, these
observations and concerns highlight the need for evi-
dence-based and practice-directed CPG recommendations
and have prompted the revisions in evidence analysis and
COR/LOE grading schema shown in Table 1.
2012 GUIDELINE SURVEY:
SUMMARY OF RESULTS AND IMPLICATIONS
To better understand the views and requirements of
the ACC/AHA CPG user, a survey was taken from Sep-
tember to October 2012. The survey was conducted via 2
online sources: 1) the ACC CardioSurve Panel, which is
composed of U.S. cardiologists who are currently active
Fellows of the ACC, and 2) an open, online survey emailed
to representative members of the ACC Board of Trustees,
AHA, Heart Rhythm Society, and Society for Car-
diovascular Angiography and Interventions. The Car-
dioSurve survey received a total of 166 responses from 450
CardioSurve panelists for a response rate of 37%. A total of
40 of 301 members of the organizations above completed
the survey for an overall response rate of 13%. Thus, the
ﬁnal number of responses for this survey was 206.
The ﬁndings of the survey are summarized as follows:
 When members were asked to rate the relevance of
weaker COR and LOE (Class IIa and IIb and LOE C) to
their practice, more than two thirds of cardiologists
indicated that the weaker class/levels were helpful or
very helpful when making informed diagnostic and
therapeutic decisions. This is an important observa-
tion, because it indicates that clinicians seek guidance
on important topics even in situations where the evi-
dence base is weak. It also suggests that focusing CPGs
only on strong evidence is not adequate for clinicians
to deliver comprehensive best practices. These obser-
vations highlight the natural tension between the value
to clinicians of a comprehensive CPG and a more
restricted CPG limited to a few recommendations
informed by a strong scientiﬁc evidence base.
 More than 90% of cardiologists found the ACC/AHA
CPGs routinely useful in clinical practice. In fact, >80%
of cardiologists apply CPGs in managing patients in
most circumstances. The CPG features found most
useful are clinical applicability and authority, brevity
and clarity, comprehensiveness, ease of access and use,
and currency.
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the most frequent use of CPGs is to address a speciﬁc
clinical question at the point of care, such as in the
ofﬁce, in the hospital, or on rounds. For cardiologists in
medical schools and universities, CPGs are most com-
monly used as a teaching tool.
 Cardiologists are almost uniformly more interested in
an electronic means to access CPGs compared with
print access alone. However, they do not have a single
preference for electronic means of accessing CPGs.
They are nearly evenly split between ACC/AHA web-
sites through topic listings, smartphone applications,
search engines, or electronic tablet applications. The
majority of cardiologists prefer a comprehensive CPG
separated into different sections or chapters, with all
sections published together as a single document.
 More than two thirds of cardiologists prefer a
“dynamic” update of CPGs, either continuously as a
“living” electronic document or as an update that
occurs whenever new information requires changes to
the content/recommendations.
 The majority of cardiologists are very or extremely
satisﬁed with the current use of a color-coded recom-
mendation table format. In addition, more than two
thirds of cardiologists prefer limited text informing the
recommendations, with links to an evidence table that
provides pertinent details of each study that can be
accessed as desired.
 Nearly three fourths of cardiologists believe that clini-
cians have a responsibility to help society provide
optimal care for all patients and that CPGs should
incorporate available information about cost/resource
utilization to educate providers, payers, and patients
about the value of various strategies.
The IOM recommendation to have CPGs informed by the
highest-quality (i.e., RCT) evidence and meta-analyses,
assessed by an independent ERC, may seem to be discordant
with the views and needs of these CPG users, that is, to
include not only strong evidence-based recommendations,
but also those based on lesser evidence and expert opinion
and to do so in a timely, concise, and accessible way. This
dilemma presents an ongoing and major challenge to the
Task Force in charting the future course for CPGs.
EVOLUTION IN CPG METHODS AND PROCESSES
To provide a balanced response to the IOM, clinicians, and
CPG users and the concern that recommendations are not
based only on the highest LOE, the following initiatives
were undertaken in 2013 and 2014:
 An ERC was established to provide an independent
systematic review of evidence related to key PICOTS
questions generated by the GWC in collaboration withthe ERC. To ensure transparency and consistency, the
ERC uses a standardized quantitative tool for assessing
RCT data and a separate standardized, quantitative tool
for grading registry/observational data.
 The challenge to generate CPGs based on a more delib-
erative, independent, and transparent approach to evi-
dence review while responding to the desire for more
timely, responsive, “living” guidelineswill be addressed
by compiling CPGs from individual recommendations,
each a concise knowledge “byte,” accompanied by con-
cise supporting text and linked to supporting references
and evidence tables (as piloted in the 2014 AHA/ACC
valvular heart disease guideline [11]) and stored in an
electronic repository. The individual recommendations
for each CPG will then be assembled together for the
web-published and print versions. Not only will these
be accessible through a variety of electronic search
strategies, enabled by a standard taxonomy, but they
will be capable of being shared among overlapping
documents and individually updated or expanded in a
“living” document fashion as new evidence becomes
available. Accessing and updating individual modules
from the electronic guideline content management
system will be much less onerous and more efﬁcient
once the initial guideline has been developed. These
documents may include revision history and can be
accessed from mobile devices at the point of care and
can eventually be integrated into electronic medical
record systems and other patient management tools.
CPG UPDATES: CURRENT PROCESS
The process for initiating, revising, and updating CPGs
continues to evolve under the direction of the Task Force.
Keeping pace with new data is an ongoing challenge in the
development of CPGs. In the early 1980s, the Task Force
established policies and procedures for maintaining the
relevancy of published recommendations. The process
involved full revisions and shorter updates. Full revision
occurred after 2 updates or when new evidence required
revision of a signiﬁcant portion of the recommendations.
Each topic was reviewed a year after publication of a CPG
document and annually thereafter. There was on average
a 4- to 5-year span between revisions of each topic.
Recognizing the necessity to review new and rapidly
changing evidence in an ongoing fashion and the time
required to initiate, develop, review, and publish a CPG,
the Task Force developed a new initiative in 2005 to
integrate an accelerated focused update process. The
GWC (whose membership often spans >1 document) and
Task Force members review late-breaking clinical trials
presented at major meetings and scan the literature
pertaining to each guideline topic twice annually.
The decision to initiate a focused update of a CPG is based
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quately powered RCTs or nonrandomized studies with
safety or efﬁcacy implications (see criteria below). They
do not require comprehensive accounting for all literature
published since the date of the previous CPG evidence
review; the evidence review period is noted in the intro-
duction of each CPG.
The criteria and considerations for new data include
the following:
 Publication of the full report (rather than the abstract)
in a peer-reviewed journal
 Adequately powered RCT(s)
 Important nonrandomized data that affect safety and
efﬁcacy assumptions
 Strengths/weaknesses of research methodology and
ﬁndings
 The likelihood that additional studies will inﬂuence the
ﬁndings or conclusions
 The impact on current performance measure(s) or the
need to develop new measures
 Requests for review and update from the practice
community, key stakeholders, and other sources free of
bias or commercial relationships
 The number of previous studies with consistent results
 Consistency with other CPGs or CPG revisions
 Approval of new drugs, devices, or applications by the
U.S. Food and Drug Administration that have an impact
on cardiovascular care
Initiation of a focused update does not imply that a
recommendation must change but rather that new evi-
dence is critically reviewed by the GWC to reach a deci-
sion. With the exception of the recommendations
modiﬁed in focused updates, the full CPG remains current.
Recommendations in focused updates are current until
superseded by another update or a full revision of the
CPG. Since the publication of the ﬁrst 2 focused updates in
2007 (12,13), they have been created as stand-alone
documents with section numbers corresponding to the
CPG and new and revised recommendations denoted in
adjacent tabular columns. The focused updates are also
incorporated into the full CPG, which is republished online
in order to provide a complete, comprehensive CPG.
CPG DERIVATIVES
The recommendations in CPGs remain the primary source
of guidance for clinicians. Access to CPGs will increasingly
be through sources other than the full, written versions of
the CPGs, including Web sites (such as those of the AHA
and ACC), pocket guides, and electronic access such as
smartphone applications. Performance measures oper-
ationalize CPG recommendations and are developed as
derivatives of CPGs by a separate task force, the ACC/AHATask Force on Performance Measures. Performance
measures focus on critical recommendations carrying
large beneﬁt based on high-quality evidence to provide
quantitative metrics for assessing the quality of patient
care for speciﬁc cardiovascular conditions. Failure to
deliver this care to an eligible patient suggests a quality
lapse. Increasingly, performance measures are used as the
basis for public reporting and pay-for-performance pro-
grams. Recommendations selected for performance
measures must be measureable, valid, reliable, and
actionable; address demonstrable gaps in care; and lead to
improved patient outcomes (14,15). Currently, the num-
ber of measures, feasibility of data collection, exceptions,
and correct attribution are under active consideration by
the ACC/AHA Task Force on Performance Measures.
The ACC appropriate use criteria documents, another
derivative of CPGs, supplement the recommendations by
providing representative clinical scenarios that allow
clinicians to document practice patterns for comparison
against established benchmarks. In addition, they address
scenarios for which evidence is lacking. The appropriate
use criteria methodology is based on the RAND (Research
And Development) Delphi model, which provides con-
sensus judgments about the utility of interventions in
speciﬁc clinical situations. Clinical scenarios are con-
structed by a committee using CPG recommendations and
are then evaluated by a separate technical panel to trans-
late and implement CPG recommendations in clinical
practice. When CPGs and appropriate use criteria docu-
ments were directly mapped against each other for coro-
nary revascularization indications in validation testing,
all Class I recommendations were appropriate and all
Class III recommendations mapped to inappropriate (16).
Whereas CPG recommendations are “should” or
“should not” directives, performance measures represent
“must do” and appropriate use criteria “reasonable to do”
clinical steps. Taken together, these documents deﬁne
best practices based on evidence, measure how con-
sistently these practices are implemented in patient care,
and facilitate benchmarking of practice patterns relative
to peers to promote quality improvement in the interest
of safe and effective patient care.
The AHA scientiﬁc statements and the ACC clinical
expert consensus documents represent another important
educational product ancillary to CPGs. These documents
provide expert opinion and evidence summaries on
important focused cardiovascular topics too narrow or
immature to warrant a full CPG but for which there is
signiﬁcant scientiﬁc and clinical interest.
ONGOING CHALLENGES
Responding to the continually expanding evidence base
in a timely manner while maintaining rigorous processes
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clinical practice, remains an ongoing challenge. The
addition of formal systematic reviews, expansion of the
peer review process to include patients and other stake-
holders, and selection of the GWC in accordance with a
strict RWI policy are time-consuming endeavors. Future
challenges in delineation of RWI policy include recog-
nition that manufacturers of recently approved devices
are typically required to provide operator training to
promote safe deployment of new technology. The ACC
and AHA encourage training of clinicians to ensure sufﬁ-
cient expertise while requiring disclosure of industry-
sponsored training by members of GWCs. Although the
delivery of timely CPGs is essential, it is also important to
balance speed with deliberation and accuracy and to
allow new treatments to adequately dwell in the clinical
arena to assess generalizability and long-term outcomes
in clinical practice.
Most apparent, particularly to members of the GWC,
are the gaps in evidence. A lack of quality studies in many
areas contributes to the relatively high proportion of LOE
C/E recommendations, particularly in the many speciﬁc
conditions and circumstances where clinicians need
guidance. Like the research on which most recom-
mendations are based, clinical science is an iterative
process in continual evolution. Initiatives such as the
AHA’s Get With the Guidelines and Mission: Lifeline and
the ACC’s Door to Balloon Alliance and Hospital2Home
have led to improvements in quality of care. However, the
relative paucity of funding for implementation science
and other barriers challenge the uptake of CPG recom-
mendations in the clinical community.
Furthermore, despite the privilege and reward of
serving on ERCs or GWCs, the requisite time commitment
may preclude participation in future endeavors as the
demands of clinical practice and academic responsibilities
continue to increase.
FUTURE DIRECTIONS
Looking to the future, it is clear that the ACC/AHA
CPG methodology will evolve in response to a changing
healthcare environment and the availability of new
formats with which to deliver recommendations. Creation
of ongoing “living” documents is under development onvarious digital platforms. Embedding CPG recom-
mendations and prompts within electronic medical record
systems and mobile devices accessible at the point of care
will require new ways of crafting and parsing information
into “bytes” of data that support individual recom-
mendations and will require resource utilization efforts.
Although past GWCs have excluded cost con-
siderations from recommendations, it is clear that with
limited healthcare resources and rising costs, it is impor-
tant and appropriate to consider cost, cost-effectiveness,
and value. Going forward, it is recommended that the
COR and LOE criteria summarizing the strength/level and
quality of evidence supporting clinical beneﬁt, based on
validated evidence assessment tools, be supplemented by
an assessment of value (17). Furthermore, although CPGs
are more broadly disease based (rather than procedure
based), the documents are sometimes crafted in silos;
recognition and incorporation of multiple comorbidities
will become increasingly important as the patient pop-
ulation ages and people live longer with more advanced
cardiovascular disease. The future also may see innova-
tions in clinical trial designs and an important interaction
between CPGs and data registries, which may expand
patient/subject subgroups of interest poorly represented
in clinical trials and create a “learning health system”
where a continuous cycle of evidence-based practice
leads to feedback of practice-based evidence to validate
and further reﬁne clinical evidence (18).
To maintain consistency and facilitate implementation
of CPG recommendations, it is important to harmonize
our CPGs with those issued by other organizations
within the United States and abroad. Notwithstanding
differences in resources, economy, RWI policies, and
availability of guideline-directed medical therapies, har-
monization across CPGs has the potential to minimize
confusion in the caregiver community and enhance
adherence to recommendations.
Perhaps most important is to preserve the steadfast
commitment to the development and dissemination of
CPGs based on a thorough, unbiased evaluation of avail-
able evidence combined with a focus on patient-centric
care and shared decision making. What will remain
unchanged is the overall goal of providing guidance to
clinicians to improve quality of care and outcomes for
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